First-in-class antibody mixture shows clinical activity against Tx-resistant, advanced CRC

Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies, was found to be clinically active in patients with advanced colorectal cancer that had become resistant to prior anti-EGFR therapies. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail